1. Introduction
===============

Caryophyllene-based sesquiterpenoids are a group of structurally unique natural products characterized by the presence of a bicyclo\[2.7.0\]undecane skeleton, in addition to the backbone-rearranged polycyclic derivatives \[[@B1-marinedrugs-12-03904]\]. The majority of caryophyllene-related analogues have been isolated from terrestrial plants \[[@B2-marinedrugs-12-03904],[@B3-marinedrugs-12-03904],[@B4-marinedrugs-12-03904]\] and the plant-associated fungal species \[[@B5-marinedrugs-12-03904],[@B6-marinedrugs-12-03904],[@B7-marinedrugs-12-03904],[@B8-marinedrugs-12-03904],[@B9-marinedrugs-12-03904],[@B10-marinedrugs-12-03904],[@B11-marinedrugs-12-03904],[@B12-marinedrugs-12-03904]\]. Marine-derived caryophyllane-type compounds were found from the soft coral *Sinularia nanolobata* \[[@B13-marinedrugs-12-03904],[@B14-marinedrugs-12-03904]\] and the gorgonian coral *Subergorgia suberosa* \[[@B15-marinedrugs-12-03904]\], while fuscoatrol A is the only caryophyllene sesquiterpene isolated from the marine fungus *Humicola fuscoatra* \[[@B16-marinedrugs-12-03904]\]. Some caryophyllene derivatives exhibited immunosuppressive \[[@B9-marinedrugs-12-03904]\], cytotoxic \[[@B15-marinedrugs-12-03904]\], and antibiotic activities \[[@B17-marinedrugs-12-03904],[@B18-marinedrugs-12-03904]\]. As part of our ongoing search for the chemical diversity from marine-derived microorganisms, the sponge (*Niphates* sp.) associated fungus *Hansfordia* *sinuosae* (WGCA-25-3A) was isolated. Chemical examination of the ethyl acetate extract of the solid fermented *H.* *sinuosae* resulted in the isolation of six new sesquiterpenoids (**1**--**6**) together with two known analogues ([Figure 1](#marinedrugs-12-03904-f001){ref-type="fig"}).

![Structures of punctaporonins H--M (**1**--**6**), punctaporonin B (**7**) and humulane (**8**).](marinedrugs-12-03904-g001){#marinedrugs-12-03904-f001}

2. Results and Discussion
=========================

2.1. Structure Elucidation
--------------------------

The molecular formula of punctaporonin H (**1**) was determined as C~17~H~26~O~5~ on the basis of its HRESIMS and NMR data, requiring five degrees of unsaturation. The IR absorptions at 3350 and 1708 cm^−1^ suggested the presence of hydroxy and carbonyl groups. Inspection of the ^13^C NMR and DEPT spectra revealed seventeen carbon resonances characterized by four olefinic carbons for two double bonds and a carbonyl carbon, while the ^1^H NMR spectrum displayed four methyl singlets, three olefinic protons, three methylene, and an oxymethine. Thus, the remaining degrees of the molecular unsaturation accounted for a bicyclic skeleton. A cyclobutane ring was evident from the COSY correlation between H-9 (δ~H~ 3.26, dd, *J* = 8.4, 11.0 Hz) and H~2~-10 (δ~H~ 1.42, 2.02) and their HMBC interactions with C-1 (δ~C~ 80.9) and C-11 (δ~C~ 40.6). Additional COSY relationships established the segments from CH-5 to CH-7 and CH-2 to CH~2~-3. The connection of the segments across a quaternary carbon C-4 (δ~C~ 72.1) was deduced by the HMBC correlations from H~3~-15 (δ~H~ 1.08 s) to C-3 (δ~C~ 44.9), C-4 (δ~C~ 72.1) and C-5 (δ~C~ 143.2), while C-4 was co-positioned by a methyl and a hydroxy group. The linkage of C-2 (δ~C~ 74.6) to C-1 and C-8 (δ~C~ 139.0) to C-9 (δ~C~ 39.0) to form a cyclononene ring was ascribed to the HMBC relationships from H-9 to C-7 (δ~C~ 123.6), C-8 and C-2, in addition to the correlations from H-7 (δ~H~ 5.81, brs) to C-9 and H-2 (δ~H~ 4.90, brd, *J* = 3.6 Hz) to C-1 and C-9. The location of a hydroxymethylene at C-8 was confirmed through the HMBC correlations from H~2~-14 (δ~H~ 3.87, 4.13, d, *J* = 13.2 Hz) to C-7, C-8 and C-9, whereas two methyl groups resonated at δ~H~ 1.03 (s) and 0.98 (s) were co-positioned at C-11 on the basis of their protons correlated to C-1, C-10 (δ~C~ 33.5) and C-11 in the HMBC spectrum. In addition, the HMBC correlation between H-2 and the acetyl carbonyl carbon (δ~C~ 170.8) clarified an acetoxy unit to be substituted at C-2. Thus, the gross structure was established as a caryophyllene-type sesquiterpene. The *J*~H-5/H-6~ (13.2 Hz) value and the NOE interaction between H-7 and H~2~-14 were in agreement with 5*Z* and 7*E* geometries. Additional NOE interactions from H~3~-12 to H-9 and H-2 indicated the same orientation of H-9 and H-2. The orientation of OH-1 was supposed to be opposite to H-9 on the basis of the NOE interaction between H-9 and H-2. The NOE correlations observed from H-15 to H-3b (δ~H~ 2.75) as well as from H-2 to H-3a (δ~H~ 1.36) indicated the opposite face of H~3~-15 toward H-2. Thus, the structure of **1** was determined as a C-2 acetoxylated punctaporonin B \[[@B6-marinedrugs-12-03904]\]. The absolute configuration of **1** was determined as 1*S*, 2*S*, 4*S*, and 9*R* by the results of the X-ray single-crystal diffraction using Flack parameters ([Supplementary Information, Tables S1--S7](#marinedrugs-12-03904-s001){ref-type="supplementary-material"} and [Figure 2](#marinedrugs-12-03904-f002){ref-type="fig"}) \[[@B19-marinedrugs-12-03904]\].

![X-ray crystal structures of punctaporonins H (**1**) and I (**2**).](marinedrugs-12-03904-g002){#marinedrugs-12-03904-f002}

The NMR spectroscopic data of punctaporonin I (**2**) were closely related to those of **1**, in fact both the compounds had the same molecular composition. However, C-6 (δ~C~ 66.1) was found to be a hydroxymethine group based on the HSQC correlation, and was located in the allylic position of the two double bonds according to the COSY and HMBC correlations observed. The latter displayed long range contacts from H~3~-15 (δ~H~ 1.83, s) to C-3 (δ~C~ 40.3), C-4 (δ~C~ 127.4) and C-5 (δ~C~ 133.4), revealing one of the double bonds to be between C-4/C-5. The comparable NOE interactions of **1** and **2** in addition to the NOE correlations from H-6 (δ~H~ 4.70) to H-9 (δ~H~ 3.04) and H~3~-15 and between H-5 (δ~H~ 5.17) and H-3b (δ~H~ 2.42, dd, *J* = 10.9, 10.8 Hz) confirmed a syn orientation for H-6 and H-9 and 4*E* geometry. Analysis of the X-ray single-crystal diffraction data ([Supplementary Information, Tables S8--S14](#marinedrugs-12-03904-s001){ref-type="supplementary-material"}) revealed the absolute configurations of **2** to be 1*S*, 2*S*, 6*R*, and 9*R.* It is noteworthy that **2** is an unstable compound, which was partly converted to 4*Z* isomer **2a** with an ratio of 5:4 (**2**/**2a**) during the measurement of 2D NMR spectra in DMSO-*d*~6~ ([Figure 3](#marinedrugs-12-03904-f003){ref-type="fig"}). This assignment was supported by the NOE interactions between H~3~-15/H-5 and H-7/H~2~-14 for **2a**.

![Auto-conversion of **2** to **2a** in DMSO.](marinedrugs-12-03904-g003){#marinedrugs-12-03904-f003}

The molecular formula of punctaporonin J (**3**) was established as C~23~H~35~NO~7~ by the HRESIMS data (*m*/*z* 438.2481 \[M + H\]^+^). The difference between **2** and **3** found in the NMR spectra was the presence of resonances of an exo-methylene at δ~H~ 4.79, 5.02/δ~C~ 119.6 and δ~C~ 143.5, an exchangeable proton at δ~H~ 7.79, and a side chain identified as (2*E*)-5-hydroxy-3-methylpent-2-enoyl group. The position of the exo-methylene group at C-4 was evident from its protons correlated to C-3 (δ~C~ 35.1), C-4 (δ~C~ 143.5) and C-5 (δ~C~ 62.5) in the HMBC spectrum. The side chain consisted of two olefinic carbons at δ~C~ 120.6 (C-2′) and 149.5 (C-3′), a carbonyl carbon at δ~C~ 166.4 (C-1′), two methylenes and a methyl carbon. The COSY relationship between H~2~-5′ (δ~H~ 2.21, t) and H~2~-6′ (δ~H~ 3.54, t), in association with the HMBC interactions from H~3~-4′ (δ~H~ 2.05, s ) to C-2′, C-3′ and C-5′ (δ~C~ 44.1) and from H-2′ (δ~H~ 5.76, s) to C-1′, C-4′ (δ~C~ 18.2) and C-5′ and the NOE interaction between H-2′ and H~2~-5′, established a (2*E*)-5-hydroxy-3-methylpent-2-enamide. The amide proton δ~H~ 7.79 (d) showing the COSY relationship with H-5 (δ~H~ 4.10, t) and the HMBC interactions with C-4, C-5 and C-6 confirmed the linkage of the amide moiety to C-5. The similar NOE interactions for the backbone of **3** and **2** in addition to the NOE correlations from H-9 (δ~H~ 3.26) to H-5 and H-6 (δ~H~ 4.36) assigned the same orientation of both H-5 and H-6 as H-9 ([Figure 4](#marinedrugs-12-03904-f004){ref-type="fig"}).

![Key HMBC, COSY and NOE correlations of **3** (ChemBioDraw Ultra 12.0, Cambridgesoft, Cambridge, MA, USA).](marinedrugs-12-03904-g004){#marinedrugs-12-03904-f004}

The structure of punctaporonin K (**4**) was determined as 2-deacetoxy analogue of **3** on the basis of the similar NMR data of both compounds with the exception of the absence of acetoxy group and the presence of a methylene at C-2 (δ~C~ 32.9, δ~H~ 1.57, 1.94, m).

The molecular formula of punctaporonin L (**5**) was established as C~17~H~26~O~5~ by its HRESIMS (*m*/*z* 333.1677 \[M + Na\]^+^) and NMR data. Comparison of the NMR data revealed the structure of **5** closely related to 6-hydroxypunctaporonin E \[[@B6-marinedrugs-12-03904]\]. The distinction was attributed to C-2 (δ~C~ 71.4) of **5** being substituted by an acetoxy group (δ~C~ 170.2, 21.4; δ~H~ 1.94, s) instead of a hydroxy group, as evident from the HMBC interaction between H-2 (δ~H~ 4.53, dd, *J* = 4.8, 11.2 Hz) and the acetyl carbonyl carbon (δ~C~ 170.2). The relative configurations of **5** were in accordance with those of 6-hydroxypunctaporonin E on the basis of the similar NOE interactions of both compounds. Since the absolute configurations of 6-hydroxypunctaporonin E were determined through X-ray diffraction, the same sign and similar magnitude of the specific optical rotations for both compounds led us to assign **5** as possessing the same absolute configurations as the known analogue.

The NMR data for punctaporonin M (**6**) were closely similar to those of **5**, except that H~3~-15 (δ~H~ 0.85, s) of **6** showed an HMBC correlation with an oxygenated methine carbon (δ~C~ 80.0, C-5) instead of an olefinic carbon, and H~2~-14 (δ~H~ 3.46, 3.53) exhibited the correlation with an olefinic carbon C-7 (δ~C~ 132.2), indicating that C-5 of **6** was substituted by a hydroxy group and an olefinic bond resided at C-6/C-7. The similar ROE correlations of **5** and **6** ([Figure 5](#marinedrugs-12-03904-f005){ref-type="fig"}), in association with the NOE interaction of H-2 (δ~H~ 4.94, dd, *J* = 5.0, 10.8 Hz) showing with H-5(δ~H~ 4.77, brs), H-9 (δ~H~ 1.98, m), and H~3~-12 (δ~H~ 1.08, s), confirmed the same face of these protons. Additional NOE interaction between H~2~-14 and H~3~-15 was in agreement with the *cis*-fusion of the bicyclic ring ([Figure 5](#marinedrugs-12-03904-f005){ref-type="fig"}).

![Key NOE interactions of **5** and **6** (ChemBioDraw Ultra 12.0).](marinedrugs-12-03904-g005){#marinedrugs-12-03904-f005}

Two known analogues were identical to punctaporonin B (**7**) \[[@B11-marinedrugs-12-03904]\] and humulane (**8**) \[[@B10-marinedrugs-12-03904]\] on the basis of the comparison of their NMR and specific optical rotations with those reported in literature.

2.2. Bioassay Results
---------------------

All compounds showed weak cytotoxic activity against a panel of tumor cell lines including human colon carcinoma HCT-8, human hepatoma Bel7402, human gastric carcinoma BGC823, human lung adenocarcinoma A549, and human ovarian carcinoma A2780 with IC~50~ values \>10 μM. These compounds also showed weak inhibitory effects against the bacterial strains of *Escherichia* *coli*, *Staphylococcus* *aureus*, *Bacillus* *thuringensis*, and *Bacillus* *subtilis* with the MIC values more than 125 μM.

Compounds **1**--**4** and **7**--**8** were tested for the lowering effects against oleic acid (OA)-elicited lipid accumulation in HepG2 liver cells. Compound **4** significantly reduced the OA-elicited lipid accumulation as measured by the oil-red O staining ([Figure 6](#marinedrugs-12-03904-f006){ref-type="fig"}) \[[@B20-marinedrugs-12-03904]\], while the lowering effects of the intracellular total cholesterol (TC) and triglyceride (TG) quantification of **4** ([Figure 7](#marinedrugs-12-03904-f007){ref-type="fig"}) were comparable to those induced by the positive control lovastatin and were in a dose dependent manner.

![Effects of compounds on oleic acid-elicited intracellular lipid accumulation. Cells were incubated with DMEM (Dulbecco's Modified Eagle Medium) + oleic acid (OA, 100 μM) for 12 h, and then treated with 10 μM of each compound with lovastatin as a positive control. The blank group was tested in DMEM alone, while DMEM + 100 μM OA was used as a negative control. Neutral lipids were determined by spectrophotometry at 358 nm after oil-red O staining. Bars depict the means ± SEM (standard error of mean) of at least three experiments. **\*\*\*** *p* \< 0.001, OA *vs.* Blank; **^†††^** *p* \< 0.001, test group *vs.* OA group.](marinedrugs-12-03904-g006){#marinedrugs-12-03904-f006}

High cholesterol and/or triglyceride problems are known to increase risk for hypertension, diabetes mellitus, obesity and others that impact on coronary artery disease \[[@B21-marinedrugs-12-03904]\]. Lipid overaccumulation in liver is also a key cause for the development of insulin resistance \[[@B22-marinedrugs-12-03904],[@B23-marinedrugs-12-03904]\]. High triglyceride levels are also a risk factor for acute pancreatitis. Decreasing lipid accumulation in liver is therefore beneficial for the prevention and treatment of diabetes. Modulating the dysregulation of lipid metabolism and decreasing the elevated levels of serum TC and TG are helpful for the treatment and prevention of cardiovascular disease \[[@B24-marinedrugs-12-03904]\]. Natural molecules such as resveratrol, cordycepin and chlorogenic acid have been investigated to be the capability of suppressing the lipogenesis and fat accumulation in liver tissues that induced obesity and diabetes \[[@B25-marinedrugs-12-03904],[@B26-marinedrugs-12-03904]\]. However, regulation of lipid accumulation in cell level by caryophyllene-based derivatives has not been reported. In the present work, we reported caryophyllene-type analogue **4** as a new natural scaffold which could potently induce the reduction of TC and TG in liver cells for the first time.

![Inhibitory effects of **4** toward triglycerides and total cholesterol. Intracellular levels of triglycerides and total cholesterol were measured by kits according to the manufacturer's instructions. Bars depict the means ± SEM of at least three experiments. **\*\*\*** *p* \< 0.001, OA *vs.* Blank; **^††^** *p* \< 0.01, **^†††^** *p* \< 0.001, test group *vs.* OA group. OA: oleic acid.](marinedrugs-12-03904-g007){#marinedrugs-12-03904-f007}

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

Optical rotations were measured using an Autopol III automatic polarimeter (Rudolph Research Co., Hackettstown, NJ, USA). Melting points were measured on JGW-360A melting point apparatus (Xmchongda, Tech. Co., Xiamen, China). IR spectra were recorded on a Thermo Nicolet Nexus 470 FT-IR spectrometer (Thermo Fisher Scientific Inc., New York, NY, USA). NMR spectra were measured on a Bruker Avance-500 FT NMR spectrometer (Bruker Co., Bremen, Germany) (500 MHz) using TMS as the internal standard. HRESIMS spectra were obtained on a FT-MS-Bruker APEX IV (7.0 T) (Bruker Co., Bremen, Germany). X-ray diffraction was obtained on Bruker D8 Advance single crystal X-ray Diffractometer (Bruker Co., Karlsruhe, Germany). TLC detection was carried out using precoated silica gel GF~254~ plates (Yantai Chem. Ind., Yantai, China). Column chromatography was performed on Silica gel (200--300 mesh, Qingdao Marine Chemical Plant, Qingdao, China). Sephadex LH-20 (18--110 μm) was obtained from Pharmacia Co. (Peapack, NJ, USA), and ODS (50 μm) was provided by YMC Co. (Kyoto, Japan) High-performance liquid chromatography (HPLC) was performed on a Waters e2695 Separation Module (Waters, Milford, USA) coupled with a Waters 2998 photodiode array detector (Waters, Milford, CT, USA). A Kromasil C~18~ semipreparative HPLC column (250 × 10 mm, 5 μm) (EKS Chemicals, Bohus, Sweden) was used for compound purification. All solvents were of analytical grade.

3.2. Fungal Material and Fermentation
-------------------------------------

The fungal strain *Hansfordia sinuosae* was isolated from the sponge of *Niphates* sp. collected from Southern China Sea. The fungus was identified by morphological observation and analysis of the ITS region of the rDNA, whose sequence data have been deposited at GenBank with the accession number KF877718. The strain (WGCA-23-3A) was deposited at the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, China. The fungal strain was cultured on slants of potato dextrose agar (PDA) at 25 °C for 10 days. Spore inoculum was prepared by suspension in distilled H~2~O to give a final spore/cell suspension of 1 × 10^6^/mL. A large scale fermentation was carried out in fifty 500 mL Fernbach flasks each containing 80 g of rice. Distilled H~2~O with sterilization brine (100 mL) was added to each flask, and the contents were soaked overnight before autoclaving at 15 lb/in^2^ (pound per square inch) for 30 min. After cooling to room temperature, each flask was inoculated with 5.0 mL of the spore inoculum and incubated at 25 °C for 35 days.

3.3. Extraction and Isolation
-----------------------------

The fermented material was extracted with EtOAc (3 × 10 L), and the organic layer was evaporated to dryness under vacuum to afford a crude extract (99.0 g). The extract was fractionated by a silica gel packed vacuum liquid chromatography (VLC) using petroleum ether--EtOAc gradient (5:1 to 1:1) as the eluent to afford six fractions (F1--F6). F4 (2.1 g) was subjected to an ODS column (10 µm) eluting with a MeOH--H~2~O gradient (from 30% to 100%) to yield five subfractions (F4A--F4E). F4A (150 mg) was subjected to a Sephadex LH-20 column eluting with MeOH to yield **8** (3.2 mg) and **7** (11.9 mg). F4E (300 mg) was separated on semipreparative HPLC (ODS) with 45% Acetonitrile-H~2~O as a mobile phase to afford **1** (3.0 mg, Rt 38.8 min) and **2** (32.3 mg, Rt 32.0 min). F5 (557 mg) was subjected to Sephadex LH-20 column eluting with MeOH to give **3** (13.0 mg) and **4** (5.8 mg), while **5** (1.8 mg, Rt 45.4 min) and **6** (3.0 mg, Rt 29.4 min) were separated by semipreparative HPLC with 36% Acetonitrile-H~2~O as a mobile phase.

**Punctaporonin H (1).** Colorless crystal. Mp. 152--154 °C, ![](marinedrugs-12-03904-i001.jpg) −83 (*c* 0.3, CH~3~OH). UV (CH~3~OH) λ~max~ 208, 198 nm; IR (KBr) ν~max~ 3350, 2961, 2934, 2870, 1708, 1530, 1383, 1263, 1122, 1024 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-12-03904-t001){ref-type="table"}; HRESIMS *m*/*z* 333.1675 \[M + Na\]^+^ (calcd for C~17~H~26~NaO~5~, 333.1672).

**Punctaporonin I (2).** Colorless crystal. Mp. 198--199 °C, ![](marinedrugs-12-03904-i001.jpg) −139 (*c* 0.22, CH~3~OH). UV (CH~3~OH) λ~max~ 216, 198 nm; IR (KBr) ν~max~ 3343, 2932, 2870, 1714, 1648, 1620, 1463, 1373, 1256, 1122 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-12-03904-t001){ref-type="table"}; HRESIMS *m*/*z* 333.1669 \[M + Na\]^+^ (calcd for C~17~H~26~NaO~5~, 333.1672).

**Punctaporonin J (3).** Colorless oil, ![](marinedrugs-12-03904-i001.jpg) −37 (*c* 0.65, CH~3~OH). UV (CH~3~OH) λ~max~ 221.1 196.5 nm; IR (KBr) ν~max~ 3326, 2939, 2873, 1715, 1664, 1633, 1537, 1438, 1373, 1260, 1047, 1026 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-12-03904-t001){ref-type="table"}; HRESIMS *m*/*z* 438.2481 \[M + H\]^+^ (calcd for C~23~H~36~NO~7~, 438.2486).

**Punctaporonin K (4).** Colorless oil. ![](marinedrugs-12-03904-i001.jpg) −64 (*c* 0.58, CH~3~OH). UV (CH~3~OH) λ~max~ 222, 195 nm; IR (KBr) ν~max~ 3295 (br), 2936, 2870, 1723, 1663, 1629, 1533, 1439, 1365, 1202, 1060 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-12-03904-t001){ref-type="table"}; HRESIMS *m*/*z* 380.2429 \[M + H\]^+^ (calcd for C~21~H~34~NO~5~, 380.2431).

marinedrugs-12-03904-t001_Table 1

###### 

^13^C and ^1^H NMR data for **1**--**6** in DMSO-*d*~6~.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No   1       2                      3       4                        5       6                                                                                              
  ---- ------- ---------------------- ------- ------------------------ ------- ----------------------- ------- ---------------------- ------- ----------------------- ------- ------------------------
  1    80.9                           81.2                             83.4                            82.7                           77.8                            77.5    

  2    74.6    4.90, brd (3.6)        76.1    5.11, dd (10.9, 4.0)     77.4    5.08, dd (9.6, 5.2)     32.9    1.57, m; 1.94, m       71.4    4.53, dd (11.2, 4.8)    70.8    4.94, dd (10.8, 5.0)

  3    44.9    1.36, d (15.8)\        40.3    2.13, dd (10.8, 4.0)\    35.1    2.19, dd (11.0, 9.6)\   28.7    1.95, brd (12.2)\      39.0    1.66, dd (12.3, 4.8)\   36.5    1.62, dd (13.0, 10.8)\
               2.75, dd (15.8, 3.6)           2.42, dd (10.9, 10.8)            2.22, dd (11.0, 5.2)            2.05, m                        1.80, dd (12.3, 11.2)           1.81, dd (13.0, 5.0)

  4    72.1                           127.4                            143.5                           148.3                          52.6                            54.4    

  5    143.2   5.75, d (13.2)         133.4   5.17, d (9.8)            62.5    4.10, t (8.0)           62.3    4.24, t (8.5)          145.6   5.71, d (5.6)           80.0    4.77, brs

  6    124.3   5.63, brd (13.2)       66.1    4.70, dd, (9.8, 4.2)     69.5    4.36, dd (9.0, 8.0)     69.6    4.43, dd (8.5,9.2)     130.1   5.61, dd (5.6, 2.6)     136.1   5.52, brd (6.0)

  7    123.6   5.81, brs              141.8   5.83, s                  133.3   5.38, d (9.0)           131.5   5.36, d (9.2)          80.3    3.94, d (2.6)           132.2   5.48, d (6.0)

  8    139.0                          136.1                            136.1                           137.2                          49.4                            53.5    

  9    39.0    3.26, dd (11.0, 8.4)   40.6    3.04, dd (10.2, 7.9)     40.8    3.26, t (10.0)          43.9    3.16, dd (9.0, 8.7)    42.7    2.00, m                 45.3    1.98, m

  10   33.5    1.42, dd (9.1, 8.4)\   33.3    1.57, dd (12.0, 10.2)\   33.8    1.43, t (10.0)\         33.7    1.46, dd (9.0, 8.7)\   35.4    1.50, m\                35.4    1.39, dd (5.0, 4.5)\
               2.02, dd (11.0, 9.1)           1.92, dd (12.0, 7.9)             2.04, t (10.0)                  2.02, t (9.0)                  2.00, m                         2.00, m

  11   40.6                           41.6                             41.0                            40.9                           41.6                            42.5    

  12   24.5    1.03, s                24.5    0.94, s                  24.7    1.08, s                 24.3    1.07, s                23.6    1.02, s                 23.7    1.08, s

  13   24.1    0.98, s                25.5    1.02, s                  24.0    0.98, s                 22.5    0.86, s                24.3    0.98, s                 24.3    0.97, s

  14   63.4    3.87, d (13.2)\        65.4    3.78, d (11.2)\          64.3    3.76, d (11.0)\         64.3    3.74, d (12.4)\        60.3    3.50, d (11.0)\         61.9    3.46, d (11.0)\
               4.13, d (13.2)                 4.11, d (11.2)                   3.94, d (11.0)                  3.90, d (12.4)                 3.93, d (11.0)                  3.53, d (11.0)

  15   31.9    1.08, s                17.5    1.83, s                  119.6   4.79, s; 5.02, s        117.9   4.66, s; 4.86, s       27.3    1.15, s                 17.8    0.85, s

  1′                                                                   166.4                           166.4                                                                  

  2′                                                                   120.6   5.76, s                 120.6   5.76, s                                                        

  3′                                                                   149.5                           149.4                                                                  

  4′                                                                   18.2    2.05, s                 18.2    2.07, s                                                        

  5′                                                                   44.1    2.21, t (6.2)           44.1    2.20, t (6.2)                                                  

  6′                                                                   59.6    3.54, t (6.5)           59.5    3.54, t (6.5)                                                  

  Ac   170.8                          170.1                            169.8                                                          170.2                           170.1   

       21.6    1.99, s                21.7    1.96, s                  21.5    1.97, s                                                21.4    1.94, s                 21.4    1.97, s

  NH                                                                           7.79, d (8.0)                   7.92, d (8.5)                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Punctaporonin L (5).** White powder. ![](marinedrugs-12-03904-i001.jpg) −48 (*c* 0.10, CH~3~OH); UV (CH~3~OH) λ~max~ 199 nm; IR (KBr) ν~max~ 3336, 2952, 2933, 2870, 1729, 1682, 1529, 1454, 1350, 1251, 1028 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-12-03904-t001){ref-type="table"}; HRESIMS *m*/*z* 333.1677 \[M + Na\]^+^ (calcd for C~17~H~26~O~5~Na, 333.1672).

**Punctaporonin M (6).** White powder. ![](marinedrugs-12-03904-i001.jpg) +49 (*c* 0.12, CH~3~OH). UV (CH~3~OH) λ~max~ 199 nm; IR (KBr) ν~max~ 3265, 2957, 2933, 2865, 1718 (br), 1463, 1377, 1249, 1017 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-12-03904-t001){ref-type="table"}; HRESIMS *m*/*z* 333.1677 \[M + Na\]^+^ (calcd for C~17~H~26~O~5~Na, 333.1672).

3.4. X-Ray Single Crystallographic Analyses
-------------------------------------------

Punctaporonin H (**1**) and punctaporonin I (**2**) were crystallized from MeOH-CH~2~Cl~2~ (1:1) at room temperature. The X-ray crystallographic data of both compounds (see [Supplementary information](#marinedrugs-12-03904-s001){ref-type="supplementary-material"}) were obtained on a Bruker SMART CCD detector employing graphite monochromated Cu-Kα radiation (operated in the φ-ω scan mode). The structures were solved by direct method using SHELXS-97 \[[@B27-marinedrugs-12-03904]\] and refined with full-matrix least-squares calculations on F2 using SHELXL-97 \[[@B27-marinedrugs-12-03904]\].

Crystal data of punctaporonin H: C~17~H~26~O~5~, *M* = 310.38, monoclinic, *a* = 9.3925(11) Å, *b* = 9.3490(9) Å, *c* = 9.8735(9) Å, *β* = 107.503(12)°, *U* = 826.86(15) Å^3^, *T* = 98.5, space group P2~1~ (No. 4), Z = 2, μ(Cu Kα) = 0.741, 5653 reflections measured, 2970 unique (*R*~int~ = 0.0315) which were used in all calculations. The final *wR*(*F*~2~) was 0.1288 (all data).

Crystal data of punctaporonin I: C~17~H~26~O~5~, *M* = 310.38, orthorhombic, *a* = 11.2742(10) Å, *b* = 11.7414(11) Å, *c* = 12.020(2) Å, *U* = 1591.2(4) Å^3^, *T* = 99.7, space group P2~1~2~1~2~1~ (No. 19), Z = 4, μ(Cu Kα) = 0.771, 5650 reflections measured, 2964 unique (*R*~int~ = 0.0301) which were used in all calculations. The final *wR*(*F*~2)~ was 0.0970 (all data).

The crystallographic data for the structures of punctaporonins H (**1**) and I (**2**) have been deposited in the Cambridge Crystallographic Data Centre (deposition numbers: CCDC 974950 for **1** and CCDC 974951 for **2**). Copies of the data can be obtained free of charge, on application to the director, CCDC \[[@B28-marinedrugs-12-03904]\], 12 Union Road, Cambridge CB21EZ, UK (Fax: +44-(0)1223-336033, or E-Mail: <deposit@ccdc.cam.ac.uk>).

3.5. Cell-Based Lipid Accumulation Assay
----------------------------------------

HepG2 cells were maintained in DMEM medium supplemented with 10% fetal bovine serum and penicillin/streptomycin (100 μg/mL). The cells with 70%--80% confluence were incubated in DMEM + oleic acid (100 μM) for 12 h, then were treated with the compounds (each, 10 μM) and a positive control lovastatin in DMEM/100 μM oleic acid with DMEM/100 μM oleic acid as a blank for additional 6 h. Subsequently, the cells were subjected to oil-red O staining or TC and TG determination as described previously \[[@B20-marinedrugs-12-03904]\]. Each experiment (*n* = 8 for oil-red O staining or *n* = 3 for TC and TG determination) was repeated in triplication.

3.6. Cytotoxic and Antibacterial Assays
---------------------------------------

The cytotoxic assay was performed by a standard MTT method. Antimicrobial activities were measured against the bacterial strains of *Escherichia* *coli*, *Staphylococcus* *aureus*, *Bacillus* *thuringensis*, and *Bacillus* *subtilis*, by the broth microdilution method. The bacteria were grown for 16 h on a rotary shaker at 37 °C. Cultures were diluted with sterile medium to achieve an optical absorbance of 0.4--0.06 at 600 nm, then further diluted 10-fold before transferring into 96-well microtiter plates. Three replicates of each compound were tested in 125 μg/mL. The optical absorbance at 600 nm was measured after cultivation for 18 h. The lowest concentrations that completely inhibited visible growth of the tested strains were recorded from three independent experiments.

4. Conclusions
==============

In biogenetic consideration, the tricyclic **5** was depicted to be derived from **1** through a transannular cyclization \[[@B29-marinedrugs-12-03904]\] by C-4/C-8 cycloaddition, whereas **6** was suggested to be derived from **5** via olefinic rearrangement. The 5-hydroxy-3-methyl-2-pentenamide unit in **3** and **4** was found from nature for the first time, while this unit was biogenetically considered to be generated through the mevalonate pathway. However, the mechanism for introducing nitrogen to form an amide instead of an ester is unknown. The significant effects of compound **4** to reduce the triglycerides and total cholesterol in the intracellular levels suggested it could be a potent lead compound for the development of a drug candidate for lowering lipids.
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